Michael Feichtinger1,2, Eytan R Barnea3,4, Atunga Nyachieo5, Mats Brännström6,7, S Samuel Kim8,9. 1. Department of Obstetrics and Gynecology, Division of Gynecologic Endocrinology and Reproductive Medicine, Medical University of Vienna, Vienna, Austria. 2. Wunschbaby Institut Feichtinger, Vienna, Austria. 3. BioIncept, LLC, Cherry Hill, NJ, 08003, USA. 4. SIEP, Society for the Investigation of Early Pregnancy, Cherry Hill, NJ, 08003, USA. 5. Institute of Primate Research, Karen, Kenya. 6. Department of Obstetrics and Gynecology, University of Gothenburg, Gothenburg, Sweden. 7. Stockholm IVF, Stockholm, Sweden. 8. University of Kansas, Kansas City, KS, USA. medssk@att.net. 9. American-Sino Women's and Children's Hospital, 155 Songyuan Rd., Shanghai, China. medssk@att.net.
Abstract
PURPOSE: Allogeneic ovarian transplantation may be an alternative in the future to oocyte donation in women with premature ovarian failure. The objectives of this study were to (a) evaluate allotransplantation feasibility for restoration of ovarian function and (b) assess efficacy of synthetic preimplantation factor (PIF) monotherapy as sole immune-acceptance regimen. METHODS: This is an experimental animal study using non-human primates (Papio anubis). Allogeneic orthotopic ovarian tissue transplantation was performed in two female olive baboons. PIF was administered as a monotherapy to prevent immune rejection and achieve transplant maintenance and function. Subjects underwent bilateral oophorectomy followed by cross-transplantation of prepared ovarian cortex. Postoperatively, subjects were monitored for clinical and biochemical signs of graft rejection and return of function. Weekly blood samples were obtained to monitor graft acceptance and endocrine function restoration. RESULTS: Postoperatively, there were no clinical signs of rejection. Laboratory parameters (alanine aminotransferase (ALT), aspartate aminotransferase (AST), blood urea nitrogen (BUN), creatinine) did not indicate organ rejection at any stage of the experiment. Initially, significant loss of follicles was noticed after grafting and serum follicle-stimulating hormone (FSH) and E2 levels were consistent with ovarian failure. Seven months after transplantation, one animal exhibited recurrence of ovarian endocrine function (perineal swelling, E2 rise, FSH decrease, and return of menstruation). CONCLUSIONS: Organ rejection after allogeneic ovarian transplantation was prevented using PIF as monotherapy for the first time and no side effects were recorded. The study suggests the clinical feasibility of ovarian allotransplantation to obtain ovarian function.
PURPOSE: Allogeneic ovarian transplantation may be an alternative in the future to oocyte donation in women with premature ovarian failure. The objectives of this study were to (a) evaluate allotransplantation feasibility for restoration of ovarian function and (b) assess efficacy of synthetic preimplantation factor (PIF) monotherapy as sole immune-acceptance regimen. METHODS: This is an experimental animal study using non-human primates (Papio anubis). Allogeneic orthotopic ovarian tissue transplantation was performed in two female olive baboons. PIF was administered as a monotherapy to prevent immune rejection and achieve transplant maintenance and function. Subjects underwent bilateral oophorectomy followed by cross-transplantation of prepared ovarian cortex. Postoperatively, subjects were monitored for clinical and biochemical signs of graft rejection and return of function. Weekly blood samples were obtained to monitor graft acceptance and endocrine function restoration. RESULTS: Postoperatively, there were no clinical signs of rejection. Laboratory parameters (alanine aminotransferase (ALT), aspartate aminotransferase (AST), blood ureanitrogen (BUN), creatinine) did not indicate organ rejection at any stage of the experiment. Initially, significant loss of follicles was noticed after grafting and serum follicle-stimulating hormone (FSH) and E2 levels were consistent with ovarian failure. Seven months after transplantation, one animal exhibited recurrence of ovarian endocrine function (perineal swelling, E2 rise, FSH decrease, and return of menstruation). CONCLUSIONS: Organ rejection after allogeneic ovarian transplantation was prevented using PIF as monotherapy for the first time and no side effects were recorded. The study suggests the clinical feasibility of ovarian allotransplantation to obtain ovarian function.
Authors: Lola Weiss; Reuven Or; Richard C Jones; Ravi Amunugama; Lellean JeBailey; Sivakumar Ramu; Steven A Bernstein; Zhanna Yekhtin; Osnat Almogi-Hazan; Reut Shainer; Israel Reibstein; Alexander O Vortmeyer; Michael J Paidas; Michael Zeira; Shimon Slavin; Eytan R Barnea Journal: J Neurol Sci Date: 2011-10-13 Impact factor: 3.181
Authors: J Donnez; M M Dolmans; D Demylle; P Jadoul; C Pirard; J Squifflet; B Martinez-Madrid; A van Langendonckt Journal: Lancet Date: 2004 Oct 16-22 Impact factor: 79.321
Authors: Vaishali B Popat; Karim A Calis; Vien H Vanderhoof; Giovanni Cizza; James C Reynolds; Nancy Sebring; James F Troendle; Lawrence M Nelson Journal: J Clin Endocrinol Metab Date: 2009-04-28 Impact factor: 5.958
Authors: Martin Mueller; Jichun Zhou; Lihua Yang; Yuan Gao; Fuju Wu; Andreina Schoeberlein; Daniel Surbek; Eytan R Barnea; Michael Paidas; Yingqun Huang Journal: Proc Natl Acad Sci U S A Date: 2014-09-09 Impact factor: 11.205